The present disclosure relates to an in vivo duct repair device and an operating method thereof. The in vivo duct repair device includes a catheter; a nozzle assembly, two axial ends thereof including a supplying end and a spraying end, respectively, the nozzle assembly having a first material flow channel arranged inside the nozzle assembly, a first material spout communicated with the first material flow channel and spraying a first material radially outwards, a second material flow channel arranged inside the nozzle assembly and isolated from the first material flow channel and a second material spout communicated with the second material flow channel and spraying a second material radially outwards, and the nozzle assembly being configured to enter the catheter and extend the spraying end out of an introducing end of the catheter; and a drive device connected to the supplying end.

Systems, devices, compositions, and methods for treating bleeding, for containing blood that has been lost by a subject due to bleeding, and for treating surfaces contaminated with blood or expected to be contaminated with blood are disclosed. The systems, devices, compositions, and methods utilize platelets, platelet-derived materials, or both. The invention includes sprayers, nebulizers, and equivalents, to deliver platelets and/or platelet-derived materials to desired surfaces. Exemplary embodiments include the use of a pressurized sprayer configured to deliver a topical administration of a lyophilized platelet and/or platelet-derived material to a surface.

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

Systems, methods and kits for treating hemorrhages within cavities are provided. The methods utilize the application of a rapid spike of pressure to the closed cavity, followed by a steady state pressure or pressures.

Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninhotis, and Xanthomonas arboricola pathovar pruni, a producer of pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described, and they may be applied to the gingival mucosa and/or alveolar mucosa on the buccal (1) or lingual/buccal (2) surfaces with extensions and anatomical contours for crowns of the upper and lower dental arches.

Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents.

Disclosed herein are hemostatic materials and methods of production and use thereof.

The invention relates to a method for producing a storable molded body made of bacterial cellulose and a molded body produced according to the method. A preferred method includes providing a molded body made of bacterial cellulose. Optionally, mechanically pressing the entire molded body or parts of the molded body at temperatures in the range of 10° C. to 100° C. and pressures in the range of 0.01 to 1 MPa for a pressing time of 10-200 min. Treating the molded body with a solution of 20% by weight to 50% by weight of glycerol and 50% by weight to 80% by weight of a C1-C3-alcohol/water mixture. Drying the treated molded body.

Exemplary methods and systems can be provided for resurfacing of skin that include formation of a plurality of small holes, e.g., having widths greater than about 0.2 mm and less than about 0.7 mm or 0.5 mm, using a mechanical apparatus. Compressive and/or tensile forces can then be applied to the treated region of skin as the damage heals to facilitate hole closure, and provide enhanced and/or directional shrinkage of the treated skin area.

Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection.